| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| ly2157299 | transforming growth factor beta 1 | NA | Successful target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of pancreas[MeSHID:D010190] Arteriosclerosis[MeSHID:D001161] Liver carcinoma[MeSHID:D006528] Pancreatic carcinoma[MeSHID:C562463] Glioma[MeSHID:D005910] Malignant Neoplasms[MeSHID:D009369] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
NA | phase 2/3 | unknown |
| ly2157299 | tgf-beta receptor type i | NA | Clinical trial target | TTD , DGIDB | Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Malignant neoplasm of pancreas[MeSHID:D010190] Arteriosclerosis[MeSHID:D001161] Liver carcinoma[MeSHID:D006528] Pancreatic carcinoma[MeSHID:C562463] Glioma[MeSHID:D005910] Malignant Neoplasms[MeSHID:D009369] Non-Small Cell Lung Carcinoma[MeSHID:D002289] |
NA | phase 2/3 | unknown |
| click here to return to the previous page | ||||||||